Conditioning regimens for children with ALL have generally included total body irradation (TBI), which may result in significant sequelae. The primary aim of this study was to evaluate the outcome for children with ALL undergoing allogeneic stem cell transplant (SCT) with either busulfan (Bu) or TBI regimens. Patients o21 years with ALL undergoing allogeneic SCT were eligible. Conditioning included either Bu or TBI, with etoposide 40 mg/kg and cyclophosphamide 120 mg/kg. Randomization was stratified based upon duration of remission, remission status, and prior cranial irradiation. A total of 43 patients were enrolled; 21 received Bu and 22 TBI. Median patient age was 8 years (0.5-20 years). Remission status included 12 patients in CR1, 25 in CR2, and six in CR3. At a median follow-up of 43 months, event-free survival (EFS) is 45% at 3 years, with 29% EFS in the Bu arm and 58% in the TBI arm (P ¼ 0.03). There was no significant difference between Bu and TBI for patients who received stem cells from related donors (36 vs 58%, P ¼ 0.3). However, for URD, EFS was 20% for Bu and 57% for TBI (P ¼ 0.04). Relapses were similar in both arms. This randomized prospective study suggests that Bu is inferior to TBI for pediatric patients with ALL undergoing allogeneic SCT.
Allogeneic stem cell transplant (SCT) may be a curative therapy for pediatric patients with ALL resistant to chemotherapy. To achieve engraftment and eradicate leukemia, conditioning therapy generally has included total body irradiation (TBI), in addition to high-dose chemotherapy. The late effects of TBI in children are well established and may include growth impairment, cataracts, hypothyroidism, and an increase in secondary malignancies. Busulfan (Bu), as an alternative to TBI, is attractive in that radiation sequelae are avoided, and it can be administered in small children without the need for sedation or anesthesia. Prospective randomized trials comparing Bu to TBI have been performed in patients with AML and CML, and the use of a cyclophosphamide dose of 120 mg/kg with Bu in adults, and 200 mg/kg in children has resulted in event-free survival (EFS) equivalent to that of TBI and 120 mg/kg of cyclophosphamide. [1] [2] [3] While Bu has been used in small numbers of patients with ALL, [4] [5] [6] [7] its efficacy and toxicity as part of the conditioning regimen have never been tested in a randomized fashion. To evaluate the efficacy and toxicity of Bu in patients with ALL, the Pediatric Blood and Marrow Transplant Consortium developed a randomized trial to compare a Bu containing conditioning regimen with a TBI conditioning regimen. Etoposide was added to the regimen for potential increase in antileukemic effect while retaining the immunosuppression of cyclophosphamide to ensure engraftment.
Patients and methods
This study opened in January 1997 and closed in October 2000. The Institutional Review Boards of the 11 participating institutions approved the protocol, and parents or guardians signed informed consent prior to randomization of therapy.
Conditioning included either oral Bu 1 mg/kg (or 40 mg/m 2 for patients p20 kg) every 6 h for 16 doses or TBI 1200 cGy/six fractions/3 days, in addition to Etopophos (Etoposide phosphate, Bristol-Myers Squibb, Princeton, NJ, USA) 40 mg/kg once daily i.v. day À4 and cyclophosphamide 60 mg/kg once daily i.v. days À3 and À2 (total dose 120 mg/kg). Bu pharmacokinetics were not obtained routinely. Patients who received Bu and unrelated donor grafts received antithymocyte globulin, 30 mg/kg/day i.v. days À2, À1, 0 for increased immunosuppression to facilitate engraftment. Additional CNS prophylaxis was given to patients who received Bu, and who had no prior CNS irradiation, as there was concern about the possibility of increased CNS relapse in these high-risk patients. Intrathecal methotrexate, starting on day +100, was administered every 3 months for six doses. Patients with prior CNS disease, and no irradiation, received 600 -cGy cranial irradiation prior to conditioning, if randomized to TBI. Patients with prior CNS disease received 1800 cGy before conditioning with Bu. Graft-versus-host disease (GVHD) prophylaxis was cyclosporine 7 methotrexate for matched siblings, cyclosporine and 'short-course' methotrexate for unrelated donor recipients, and cyclosporine/methylprednisolone for cord blood recipients. Supportive care was not uniformly mandated, but all patients received phenytoin for seizure prophylaxis if they received busulfan.
Engraftment was defined as achievement of an absolute neutrophil count 4500 for 3 consecutive days. Chimerism analysis was not generally available. GVHD was graded by commonly accepted criteria. 8 Late effects studies included neuropsychologic, pulmonary, cardiac, endocrine, and ophthalmologic evaluations.
Statistical analysis
Patients were randomized based upon stratification for duration of first remission (less than or greater than 18 months), remission status and prior CNS irradiation. Randomization was performed within 1 month of projected SCT.
Patient status was determined as of 31 January 2003. Clinical data were collected on case report forms and were then entered into a relational database developed in Access 97. Data were exported into STATA 7.0 for statistical analysis. Patient characteristics, toxicity, and GVHD were summarized with descriptive statistics. Kaplan-Meier was used to describe overall survival (OS) and EFS. The Wilcoxon rank-sum test was used to compare survival between groups. Cox's proportional-hazards analysis was used for multivariate analysis. All P-values were two sided. Interim analyses of relapse and nonrelapse mortality were performed every 6 months.
Results
Clinical characteristics and transplant details are listed in Table 1 . There were 29 boys and 14 girls enrolled. The median age at SCT was 8.7 years (range 0.7-20 years). For patients in first remission (CR1), the median time from diagnosis to BMT was 5.7 months (range 3.6-11.5 months). All CR1 patients had either t(4;11) or t(9;22). For other patients, the median time from diagnosis to transplant was 40.2 months (range 9.8-82.4 months). There were 20 related donors, and 19 were matched siblings. One was a parent mismatched at the B locus. Two of four cord bloods were mismatched at a single locus. All unrelated donors were matched by serology at class I, and matched at DRB1.
A total of 42 patients engrafted. One patient, who received Bu, and a related donor mismatched at B, failed to engraft. In total, 21 patients are alive and disease -free at 13-63 months post transplant. The median follow-up for surviving patients is 43.3 months (range 13-64 months). OS at 3 years is 47% for Bu patients, and 67% for TBI patients (P ¼ 0.09). EFS is 45% at 3 years, with 29% for Bu patients and 58% for TBI patients (P ¼ 0.03).
Relapses occurred in nine patients who received busulfan and seven who received TBI at a median of 6.4 months (range 3.2-28.7 months) ( Table 2) . Five patients had isolated extramedullary relapses, including skin, bone, testes, CNS. Four patients, who had received Bu, underwent a second transplant with TBI regimens. Three were retransplanted for relapse, and one for graft failure. Three are alive and well at 10, 12, and 27 months post second transplant; one patient died of pulmonary insufficiency. Three other patients remain in remission following additional chemotherapy at 3, 22, and 29 months post relapse. Acute GVHD developed in 11 patients, and was grades III-IV in two patients. Chronic GVHD occurred in four patients, and was limited in two. Seven patients died of non-relapse causes ( Table 2 ). All but one patient died oday 60; the cause of death of the patient who died at day 270 was attributable to complications from chronic GVHD.
Donor source, patient age, and CR status were determinants of outcome when stratified by conditioning regimen at 3 years of follow-up. Overall, there was no difference in EFS between patients who received stem cells from related donors vs those who received unrelated donor cells (46 vs 40%, P ¼ 0.3). There was a trend toward improved EFS for MRD recipients who received TBI, 58%, compared to those who received Bu, 36%, but this was not statistically significant. However, for patients who received unrelated donor stem cells, EFS was inferior with Bu, 20% in contrast to 57% with TBI (P ¼ 0.04) (Figure 1 ). EFS was 42% for patients under 6 years of age and years, and 44% for those older than 6 years (P ¼ 0.5). Patients less than 6 years had an inferior EFS with Bu conditioning, P ¼ 0.056 (Table 3 ). There was no significant difference in outcome between patients transplanted in first or second remission (TBI EFS of 66% vs Bu EFS 46%) at 3 years. However, patients transplanted with TBI in CR1 had a significantly improved survival over patients transplanted in CR1 with Bu, P ¼ 0.045 (Table 3 ). Only one of seven patients transplanted in third remission remains alive at 18 months.
Cox's proportional-hazards analysis was performed using variables defined on univariate analysis as significant and variables known to modify EFS. A backward stepwise selection logic was employed to evaluate six variables: age, gender, ethnicity, donor type, CR status, and conditioning. In this analysis, conditioning with Bu was significantly associated with an increased risk of relapse with a threefold increase in the risk of relapse-or transplant-related mortality (Table 4) . This relationship was statistically significant at P ¼ 0.025 despite the sample size requirements of logistic regression. 9 Donor type approached but did not reach statistical significance and the other evaluated covariates were not statistically significant. Follow-up studies were obtained inconsistently, and age precluded pulmonary function studies for young patients. The Lansky activity scores were 90 for one patient with bronchiolitis obliterans, and 100 for 17 others. Follow-up pulmonary function studies were available for six patients who received TBI; one patient has bronchiolitis obliterans associated with chronic GVHD, and one has mild obstructive disease. Of the five patients who received Bu for whom pulmonary function tests are available, two have mild obstructive disease, one has moderate restrictive disease, one has both mild obstructive/restrictive disease, and one has normal pulmonary function. Cardiac function showed no change in 13 patients for whom follow-up is available. Neuropsychologic evaluations are available for nine patients. For six patients who received TBI, two showed no change in follow-up evaluations, and four have demonstrated decreased performance and/or full scale IQ. For two patients who received Bu, there was no change on neuropsychologic testing.
Discussion
This prospective study was initiated because of concerns regarding the significant sequelae of TBI conditioning regimens in children. Morbidities of TBI are well established, and include cataracts, hypothyroidism, poor growth, and neurocognitive effects, as well as a significantly higher cancer risk. [10] [11] [12] [13] [14] Other studies have supported the lack of effect upon growth with Bu compared to TBI. [15] [16] [17] Bu reduced the risk of post-transplant growth impairment, thyroid dysfunction, and cataracts. 18 While other studies have shown encouraging results with Bu in pediatric ALL patients, these were single arm studies limited to single institutions. [5] [6] [7] Lenarsky reported 14 children who received Bu/cyclophosphamide; 8 received allogeneic marrow. Seven of these patients were disease free, although follow-up was short. 5 von Bueltzingsloewen et al 7 used Bu and other agents, including cyclophosphamide or melphalan or etoposide, for 21 children less than 4 years with ALL. The overall LFS was 61%, and there were no transplantrelated deaths. 7 Small adult studies have also utilized Bu for ALL. In a study by Copelan et al 19 39 adult patients with ALL were treated with a Bu/cyclophosphamide regimen. In the 27 patients in CR1, LFS was 42% at 3 years. For more advanced disease, however, the LFS was only 13.5%.
Accrual was smaller than anticipated on this study due to other institutional commitments within the Pediatric Blood and Marrow Transplant Consortium. However, our study suggests that the outcome of pediatric patients with ALL may be inferior with Bu compared to TBI. Despite the small number and variability of patients studied, our randomized trial demonstrates a statistically significant difference between Bu and TBI conditioning in 3 year EFS. This statistically significant difference was seen in both Kaplan-Meier analysis and Cox's models of event risk. Thus, despite the small number of patients in this trial, the randomized design and statistically significant results argue for a difference in efficacy between TBI-and Bu-based conditioning regimens for pediatric relapsed ALL. While the number of patients in each conditioning arm was small, patients younger than six and those receiving unrelated donor BMT fared the worst with Bu conditioning. However, Bu did not appear to increase the risk of relapse and may therefore be efficacious for some children. Of note, successful retransplantation may be possible in some patients who received Bu, and three patients in this study were salvaged.
Etoposide has been successfully combined with TBI and cyclophosphamide to intensify the preparative regimen and decrease relapse. 20 Etoposide with cyclophosphamide and Bu has been used in children with leukemias 7, 21, 22 and this combination was the subject of a pilot feasibility study by the Pediatric Blood and Marrow Transplant Consortium. 23 In the studies by Emminger, von Bueltzingsloewen, and the PBMTC, no unexpected toxicities were noted with the addition of etoposide, and the decision was made to include this drug to decrease relapses potentially. However, the addition of etoposide has not been demonstrated to offer an advantage when added to Bu/cyclophosphamide in patients with leukemias in a prospective study. Studies in adults with leukemias and lymphomas have noted an increase in hepatotoxicity, including veno-occlusive disease (VOD), dermatologic toxicity, and mucositis, [22] [23] [24] [25] without an increase in treatment-related mortality.
A recent retrospective analysis by the IBMTR comparing Bu to TBI for children with ALL who received a matched sibling donor transplant demonstrated inferior results for Bu. 26 The Bu group included more patients less than 5 years of age, and more patients in the TBI group received drugs in addition to cyclophosphamide, and T-cell-depleted grafts. Bu levels were not obtained routinely. Similar to our prospective study, the incidence of relapse was similar in each group, suggesting that Bu may not be inferior to TBI in preventing relapse. However, non-relapse mortality, including VOD and interstitial pneumonitis, was higher in the Bu group, and LFS was superior in the TBI group (50 vs 35%, P ¼ 0.005).
The small number of patients in our study limits a conclusive analysis of the differences in nonrelapse mortality. However, other studies have noted increased transplant related toxicity in recipients of Bu, specifically hemorrhagic cystitis and VOD. 27 A randomized Nordic trial in children and adults with leukemia demonstrated no statistically significant differences in outcome between Bu or TBI regimens, although VOD, hemorrhagic cystitis, and severe GVHD were more common in patients receiving Bu. 1 This trial included 38 patients with ALL. All patients received marrow from matched sibling donors. Bu was associated with more VOD and hemorrhagic cystitis. Obstructive bronchiolitis was also higher in the Bu group, 26% vs 5% with TBI. The 7-year nonrelapse mortality was significantly higher in the Bu group, 21%, in contrast to 12% for TBI patients. This difference was more marked for patients with advanced disease; patients with early disease, as defined by first remission of acute leukemia or first chronic phase of CML, had no difference in transplantrelated mortality between Bu and TBI. 28 Another retrospective matched-pair comparison of the two regimens from the European Transplant Group for Blood and Marrow Transplant demonstrated no differences between regimens. 29 There were 246 ALL patients in this study. A recent analysis of four studies of patients with AML or CML who received either Bu or TBI has demonstrated no differences in survival or late complications with at least 7 years of follow-up. 30 No differences in late pulmonary complications were noted between the two regimens. These findings are in contrast to those of the Nordic study, which showed an increased risk of chronic GVHD, obstructive lung disease, and alopecia. 28 None of these European studies have shown the increased risk of interstitial pneumonitis found in the recent IBMTR analysis by Davies et al. 26 It is possible that preceding chemotherapy, including methotrexate, may contribute to this event in pediatric patients with ALL, but this is unclear.
Bu pharmacokinetics were not routinely evaluated during our study. The effects of Bu, both in terms of engraftment and toxicity, may be dependent upon pharmacokinetics, particularly in children. 31, 32 The pharmacokinetics of Bu are age-dependent; total plasma clearance rate is two to four times higher in children than in adults. 33, 34 This may explain the lower incidence of Burelated toxicities, such as mucositis and hepatic toxicity, generally seen in young children compared to adults. 35 Larger doses, or dosing based upon body surface area, have been proposed for children in an attempt to overcome the problems encountered with lower plasma levels. 36 However, these higher doses may increase the incidence and mortality of VOD, or result in neurotoxicity. Higher dosing based upon body surface area has failed to overcome the problem of wide interindividual variation. 34 Targeting levels following the first Bu dose may alleviate morbidity from under or over dosing, but intraindividual variation is also common. 37 Decreased concentration of Bu in young patients may have contributed to their inferior outcome in our study, and most of these young patients also received transplants from unrelated donors.
In a recent study in children with AML, there was no significant correlation between relapse risk and Bu levels. 38 The appropriate range of steady-state concentration of Bu may be different in children with ALL, compared to those with acute myeloid leukemia or nonmalignant diseases. Children with ALL differ from those studied previously, in that most of these patients have had extensive prior exposure to hepatotoxic agents, including methotrexate and mercaptopurine. This prior exposure may significantly impact upon toxicity with projected Bu plasma levels used for patients with other diseases. The prior exposure to hepatotoxins may account for the increased transplantrelated mortality seen in the IBMTR retrospective study.
Bu pharmacokinetics and targeting of levels may improve results by decreasing transplant-related mortality, and should be performed in children who receive this agent for conditioning. Prospective, randomized trials are valuable in defining risk factors, and should be encouraged to evaluate both changes in conditioning regimens and supportive care for pediatric patients. Significant concerns regarding late effects, particularly secondary cancers, continue to make conditioning without radiation a potential attractive option, but additional studies are required to develop a safe, effective regimen.
